| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
82,625,000 |
| Market
Cap: |
187.56(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.59 - $8.14 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Coherus BioSciences is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of immunotherapies to treat cancer. Co. in-licensed its lead immuno-oncology product candidate, toripalimab (CHS-007), an anti-PD-1 antibody, from Shanghai Junshi Biosciences Co., Ltd. Toripalimab is being evaluated in late-stage clinical trials for the treatment of a range of tumor types. Co.'s commercial portfolio includes two U.S. Food and Drug Administration-approved biologics, including UDENYCA® (pegfilgrastim-cbqv), a biosimilar to Neulasta®, a granulocyte-colony stimulating factor and YUSIMRY™ (adalimumab-aqvh), its Humira® (adalimumab) biosimilar product.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
223,100 |
223,100 |
223,100 |
| Total Sell Value |
$0 |
$449,770 |
$449,770 |
$449,770 |
| Total People Sold |
0 |
1 |
1 |
1 |
| Total Sell Transactions |
0 |
1 |
1 |
1 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Healy James |
Director |
– • – |
2018-08-29 |
4 |
AS |
$20.50 |
$512,500 |
I/I |
(25,000) |
2,868,221 |
|
- |
|
| Finck Barbara K |
Chief Medical Officer |
• – – |
2018-08-13 |
4 |
AS |
$19.02 |
$33,480 |
D/D |
(1,760) |
37,043 |
|
- |
|
| Finck Barbara K |
Chief Medical Officer |
• – – |
2018-08-13 |
4 |
OE |
$1.42 |
$2,499 |
D/D |
1,760 |
38,803 |
|
- |
|
| Viret Jean-Frederic |
Chief Financial Officer |
• – – |
2018-07-23 |
4 |
AS |
$18.56 |
$172,472 |
D/D |
(9,291) |
3,779 |
|
- |
|
| Finck Barbara K |
Chief Medical Officer |
• – – |
2018-07-10 |
4 |
AS |
$15.00 |
$18,900 |
D/D |
(1,260) |
37,043 |
|
- |
|
| Finck Barbara K |
Chief Medical Officer |
• – – |
2018-07-10 |
4 |
OE |
$1.42 |
$1,789 |
D/D |
1,260 |
38,303 |
|
- |
|
| Finck Barbara K |
Chief Medical Officer |
• – – |
2018-07-09 |
4 |
AS |
$15.03 |
$7,515 |
D/D |
(500) |
37,043 |
|
- |
|
| Finck Barbara K |
Chief Medical Officer |
• – – |
2018-07-09 |
4 |
OE |
$1.42 |
$710 |
D/D |
500 |
37,543 |
|
- |
|
| Finck Barbara K |
Chief Medical Officer |
• – – |
2018-06-18 |
4 |
AS |
$15.00 |
$26,400 |
D/D |
(1,760) |
37,043 |
|
- |
|
| Finck Barbara K |
Chief Medical Officer |
• – – |
2018-06-18 |
4 |
OE |
$1.42 |
$2,499 |
D/D |
1,760 |
38,803 |
|
- |
|
| Lanfear Dennis M |
See Remarks |
• • – |
2018-05-16 |
4 |
S |
$16.26 |
$341,265 |
I/I |
(20,984) |
1,316,582 |
|
- |
|
| Finck Barbara K |
Chief Medical Officer |
• – – |
2017-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
7,545 |
34,336 |
|
- |
|
| Lanfear Dennis M |
See Remarks |
• • – |
2017-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
20,984 |
92,619 |
|
- |
|
| Watler Peter K. |
Chief Technical Officer |
• – – |
2017-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,900 |
5,900 |
|
- |
|
| Herman Alan C. |
Chief Scientific Officer |
• – – |
2017-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
809 |
50,460 |
|
- |
|
| Viret Jean-Frederic |
Chief Financial Officer |
• – – |
2017-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
6,966 |
9,958 |
|
- |
|
| Temasek Holdings Ltd |
10% Owner |
– – • |
2017-08-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,556,116 |
|
- |
|
| Herman Alan C. |
Chief Scientific Officer |
• – – |
2017-08-08 |
4 |
AS |
$15.02 |
$263,300 |
D/D |
(17,535) |
49,651 |
|
- |
|
| Herman Alan C. |
Chief Scientific Officer |
• – – |
2017-07-05 |
4 |
AS |
$15.00 |
$9,000 |
D/D |
(600) |
67,186 |
|
- |
|
| Herman Alan C. |
Chief Scientific Officer |
• – – |
2017-06-01 |
4 |
AS |
$20.20 |
$230,292 |
D/D |
(11,333) |
67,786 |
|
- |
|
| Wahlstrom Mats |
Director |
– • – |
2017-05-09 |
4 |
A |
$0.00 |
$0 |
I/I |
109,957 |
219,914 |
|
- |
|
| Wahlstrom Mats |
Director |
– • – |
2017-05-09 |
4 |
D |
$0.00 |
$0 |
I/I |
(200,000) |
178,528 |
|
- |
|
| Herman Alan C. |
Chief Scientific Officer |
• – – |
2017-05-01 |
4 |
AS |
$20.00 |
$226,626 |
D/D |
(11,333) |
79,119 |
|
- |
|
| Herman Alan C. |
Chief Scientific Officer |
• – – |
2017-04-03 |
4 |
AS |
$20.73 |
$234,985 |
D/D |
(11,333) |
90,452 |
|
- |
|
| Wahlstrom Mats |
Director |
– • – |
2017-02-22 |
4 |
A |
$0.00 |
$0 |
I/I |
109,957 |
109,957 |
|
- |
|
312 Records found
|
|
Page 8 of 13 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.10 (4.61%) 
